The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma

Isabella Lurje1 | Zoltan Czigany2 | Sarah Eischet2 | Jan Bednarsch2 | Tom Florian Ulmer2 | Peter Isfort3 | Pavel Strnad4 | Christian Trautwein4 | Frank Tacke1,4 | Ulf Peter Neumann2,5 | Georg Lurje2

1Department of Hepatology and Gastroenterology, Campus Charité Mitte, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
2Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany
3Institute of Radiology, University Hospital RWTH Aachen, Aachen, Germany
4Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany
5Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands

Correspondence
Georg Lurje, Department of Surgery, Campus Charité Mitte I Campus Virchow Klinikum, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Email: georg.lurje@charite.de

Present address
Georg Lurje, Department of Surgery, Campus Charité Mitte, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany

Funding information
German federal and state governments, Grant/Award Number: G and (DE-82) ZUK2-SF-OPSF443; RWTH Aachen University, Grant/Award Number: #136/17 and #23/19

Abstract
Cholangiocarcinoma (CCA) is a rare but highly aggressive malignancy of the biliary system. Although it is amenable to surgical resection in early disease, outcomes are frequently dismal. Here, we investigated the prevalence of body composition (BC) alterations and their prognostic role for surgical patients with intrahepatic (iCCA) and perihilar (pCCA) disease. Patients undergoing curative-intent surgery for iCCA or pCCA between 2010 and 2019 at University Hospital Aachen were included. Axial computed tomography images were retrospectively assessed with a segmentation tool (3D Slicer) at the level of the third lumbar vertebra to determine lumbar skeletal muscle (SM) index, mean SM radiation attenuation, and visceral fat area. The related BC pathologies sarcopenia, myosteatosis, visceral obesity, and sarcopenic obesity were determined using previously described cutoffs. A total of 189 patients (86 with iCCA, 103 with pCCA) were included. Alterations of BC were highly prevalent in iCCA and pCCA, respectively: sarcopenia, 33% (28/86) and 39% (40/103); myosteatosis, 66% (57/86) and 66% (68/103); visceral obesity, 56% (48/86) and 67% (69/103); sarcopenic obesity, 11% (9/86) and 17% (17/103). Sarcopenia and myosteatosis did not have a significant prognostic role for disease-free survival (DFS) and overall survival (OS). Patients with iCCA with sarcopenic obesity (n = 9) had significantly shorter OS than patients without sarcopenic obesity (n = 7; log-rank p = 0.002; median OS, 11 months and 31 months; 1-year mortality, 55.6% [5/9] and 22% [17/77]; 5-year mortality, 88.9% [8/9] and 61% [47/77], respectively). In multivariable analysis, only tumor-related risk factors remained prognostic for DFS and OS. Sarcopenic obesity may affect clinical outcomes after curative-intent surgery.
INTRODUCTION

Cholangiocarcinoma (CCA) is a highly aggressive epithelial malignancy of the bile ducts that is estimated to account for 3% of all gastroenterological tumors. Surgical resection represents the cornerstone of treatment, but only approximately 30% of CCAs are amenable to curative resection due to intrahepatic and extrahepatic tumor spread. The most common anatomical subclassification of CCA is the division into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) disease. The most common subset, pCCA, comprises 50%–60% of CCAs and arises above the cystic duct and below the second-order bile ducts. iCCAs originate above the second-order bile ducts and account for 10%–20% of CCAs, while dCCAs make up 20%–30% of all CCAs. The most common risk factors for CCA are primary sclerosing cholangitis, cirrhosis, bile duct cysts (including Caroli’s disease), hepatic cholelithiasis and cholelithiasis, as well as certain parasitic infections.

Patients with CCA have a dismal oncological prognosis, and their disease is frequently accompanied by worsening of the general medical condition characterized by jaundice, cholangitis, unintentional weight loss, cachexia, and frailty. While cachexia—the severe involuntary loss of lean body mass due to systemic inflammation and metabolic deregulation—is a well-characterized hallmark of advanced disease and confers unfavorable outcomes across numerous cancer entities, the worldwide obesity epidemic has led to an increasing proportion of patients with masked wasting symptoms at presentation. In this regard, expanding the analysis of body composition (BC) beyond classical metrics, like body mass index (BMI), has the potential to reveal wasting and alterations of lean tissues and is of prognostic value in oncological disease and liver disease. As such, the quantification of muscle mass to detect sarcopenia has gained wide recognition as a prognostic parameter in solid tumors and in the progression of end-stage liver disease. More recently, myosteatosis, a qualitative characteristic of muscle composition, also emerged as a prognostic parameter in patients undergoing liver transplantation. To date, little is known about the incidence of BC alterations in patients with surgical iCCA and pCCA and about the prognostic value of these as covariates.

We hypothesized that sarcopenia, myosteatosis, visceral obesity, and sarcopenic obesity may impact the disease course of CCA. In this study, we aimed to investigate the prognostic value of computed tomography (CT)-based diagnosis of BC pathologies in patients undergoing curative resection for iCCA and pCCA.

MATERIALS AND METHODS

Patients

Between May 2010 and December 2019, all consecutive patients undergoing curative-intent surgery for iCCA and pCCA at the University Hospital RWTH Aachen, Aachen, Germany, were considered for inclusion. Exclusion criteria were defined as (i) CT scans older than 3 months and/or those not including images from the third lumbar vertebra (L3) level or only other imaging modalities, like magnetic resonance imaging (MRI), available; (ii) patients with dCCA, ampullary carcinoma, pancreatic adenocarcinoma, and (iii) neuroendocrine tumors. Clinicopathological and survival data were collected from a prospective institutional database. Preoperatively, all patients underwent a detailed workup to exclude systemic disease and to determine the extent of hepatic and hilar disease. This encompassed CT or gadolinium-enhanced MRI and endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography, as described. The institutional surgical approach included a hilar en bloc resection for pCCA, as described. The subsequent histopathological examination was standardized according to current versions of national guidelines, World Health Organization, and Union Internationale Contre le Cancer (UICC) classifications.

This study was conducted in accordance with the current version of the Declaration of Helsinki and good clinical practice guidelines (International Conference on Harmonization, Good Clinical Practice). Approval was granted by the institutional review board (EK 341/21). Informed consent was waived by the institutional review board (EK 341/21) due to the retrospective study design and analysis of available clinical data.

Segmentation and BC analysis

All CT scans were performed on a state-of-the-art multislice CT scanner. The technical parameters of CT imaging have been described. An axial CT image at the L3 vertebra level from the most recent CT image was retrieved from the Picture Archiving and
Communication System for semiautomatic segmentation of skeletal muscle and adipose tissue on the 3D Slicer software platform and BC module (https://www.slicer.org/, version 4.1). Skeletal muscle was identified and quantified at attenuation values of −29 to 150 Hounsfield units (HU), with the muscle area on level L3 including psoas major, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and rectus abdominis. Skeletal muscle index (SMI) was calculated by normalizing muscle area in square centimeters to patient stature in square meters. Skeletal muscle radiation attenuation (SM-RA), indicative of muscle density and myosteatosis, was quantified in HUs. Visceral fat area (VFA) was based on attenuation values −150 to −50 HU, and subcutaneous adipose tissue was based on attenuation values −190 to −30 HU. All measurements were performed by the same investigator who was blinded for the clinical outcome of these patients.

BMI was defined as weight in kilograms/height^2 in square meters, with values ≥25 kg/m^2 indicative of overweight/obesity. The definition of BC pathologies followed cancer-specific cutoffs described and validated in large patient cohorts as prognostic factors in gastrointestinal malignancies[7,18] to avoid an overfitting to our statistically small data set without an independent validation cohort. The cutoff for sarcopenia was SMI < 41 cm^2/m^2 in women and <43 cm^2/m^2 in men with BMI < 25 kg/m^2, and <53 cm^2/m^2 in women and men with BMI ≥ 25 kg/m^2. Myosteatosis was assigned at levels of <41 HU for patients with a BMI < 25 kg/m^2 and <33 HU for patients with a BMI ≥ 25 kg/m^2.[7] VFA ≥ 100 cm^2 was used as a cutoff for visceral obesity, while sarcopenic obesity was diagnosed in patients with BMI ≥ 25 kg/m^2 and SMI ≤ 38.5 cm^2/m^2 in women and ≤52.4 cm^2/m^2 in men, as reported for cancer patients by Tan et al.[18] (Figure 1).

Study endpoints

Associations between pathological markers of tumor aggressiveness (lymph node invasion, perineural, lymphovascular and vascular invasion, multiocularity, tumor size) with the incidence of BC pathologies were assessed. The incidence of perioperative complications in patients with BC alterations was tested. We classified 90-day postoperative complications according to the Clavien-Dindo (CD) classification,[19] and the comprehensive complication index (CCI) was calculated as described.[20] Posthepatectomy liver failure (PHLF) was evaluated as a surrogate marker for overall function and hepatic reserve. PHLF was defined according to guidelines of the International Study Group of Liver Surgery (ISGLS)[21] as elevated international normalized ratio (INR) (>1.15) and concomitant hyperbilirubinemia (>1.2 mg/dL) on postoperative day 5 in patients with previously normal values and rising INR and bilirubin in patients with preoperatively elevated values. Grade B/C PHLF was defined according to ISGLS guidelines as laboratory PHLF diagnosis requiring clinical intervention. Textbook outcomes, a composite measure for desirable postoperative outcomes, were defined according to Merath et al.[22] as (1) no prolonged length of hospital stay, (2) no readmission 90 days after discharge, and (3) no 90-day postoperative mortality along with testing for association with BC pathologies.

The cohort was dichotomized at the median age of the cohort (65 years) for univariable analysis. A tumor
### Table 1 | Select patient and clinicopathological characteristics

| Patient characteristic | Intrahepatic CCA (n = 86) | Perihilar CCA (n = 103) |
|------------------------|---------------------------|-------------------------|
| **Age (years)**        | 65±11.4                   | 66±10.4                 |
| **BMI (kg/m²)**        | 26±4.3                    | 25.8±4.7                |
| **Sex ratio (F:M), n (%)** | 49 (57.0): 37 (43.0) | 32 (31.1): 71 (68.9) |
| **EBD (stent), n (%)** | 14 (16.3)                 | 82 (79.6)               |
| **PBD, n (%)**         | 1 (1.2)                   | 23 (22.3)               |
| **Portal vein embolization, n (%)** | 8 (9.3)  | 44 (42.7)               |
| **Neoadjuvant chemotherapy, n (%)** | 3 (3.5) | 0 (0.0)                 |
| **Laparoscopic approach n (%)** | 5 (5.8) | 22 (21.4)               |
| **Operative procedure n (%)** |                       |                         |
| Atypical/anatomical resection/ bisegmentectomy | 19 (22.1) | 1 (1.0)               |
| Right hepatectomy      | 15 (17.4)                 | 9 (8.7)                 |
| Left hepatectomy       | 11 (12.8)                 | 11 (10.7)               |
| Extended right hepatectomy | 8 (9.3)  | 18 (17.5)               |
| Extended left hepatectomy | 8 (9.3)  | 26 (25.2)               |
| Right trisectorectomy  | 6 (7.0)                   | 21 (20.4)               |
| Left trisectorectomy   | 8 (9.3)                   | 6 (5.8)                 |
| Hepatoduodenectomy     | 0 (0.0)                   | 9 (8.7)                 |
| ALPPS                  | 11 (12.8)                 | 2 (1.9)                 |
| **Lymphadenectomy, n (%)** | 75 (87.2) | 103 (100.0)             |
| **Vessel replacement n (%)** | 54 (62.8) | 94 (91.2)               |
| Venous                 | 54 (62.8)                 | 87 (84.5)               |
| Arterial               | 0 (0.0)                   | 1 (1.0)                 |
| Both                   | 0 (0.0)                   | 6 (5.8)                 |
| **Operation time (minutes)** | 297.7 ±99.2 | 425.4 ±99.0             |
| **Intraoperative blood transfusions (units)** | 0.8 ±1.8 | 1.3 ±1.7               |
| **Intraoperative FFP (units)** | 1.7±2.8 | 3.2±3.2                |
| **T category, n (%)**  |                          |                         |
| Tis                    | 1 (1.2)                   | 0 (0.0)                 |
| T1                     | 24 (28.0)                 | 8 (7.5)                 |
| T2                     | 54 (62.8)                 | 57 (56.3)               |
| T3                     | 4 (4.7)                   | 27 (26.2)               |
| T4                     | 2 (2.3)                   | 9 (8.7)                 |
| **N category, n (%)**  |                          |                         |
| N0                     | 47 (54.7)                 | 58 (56.3)               |
| N1                     | 30 (34.9)                 | 32 (31.1)               |
| N2                     | 12 (11.7)                 |                         |
| **R category, n (%)**  |                          |                         |
| R0                     | 64 (74.4)                 | 77 (74.8)               |
| R1                     | 9 (10.5)                  | 16 (15.5)               |
| Rx                     | 9 (10.5)                  | 9 (8.7)                 |
| **(Micro-)vascular invasion, n (%)** | 33 (38.4) | 26 (25.2)               |
| Portal vein infiltration, n (%) | 2 (2.3) | 5 (4.9)                  |
| Hepatic artery infiltration, n (%) | 0 (0.0) | 9 (8.7)                 |
| Lymphovascular invasion, n (%) | 21 (24.4) | 21 (20.4)               |
| Perineural invasion, n (%) | 17 (19.8) | 68 (66.0)               |

(Continues)
size of 5 cm for iCCA and 3 cm for pCCA was used to dichotomize the cohort as in previous multicentric experiences and prognostic scores.[23,24]

Statistical analysis

Comparisons between groups of patients were performed with Fisher's exact test and chi-squared test for categorical variables and Mann-Whitney U test for continuous variables. Two-sided testing was performed in all instances.

Primary outcome measures were disease-free survival (DFS), defined as the time between surgery and recurrence or censoring, and overall survival (OS) from surgery until death. Patients were censored at the time of last contact and, for DFS, even if they died without recurrence. Kaplan-Meier survival curves and log-rank tests were used to assess survival. Further, univariable and multivariable Cox regressions were employed for survival analyses and to determine hazard ratios (HRs). Owing to the large number of examined parameters, only clinically significant covariates in univariable analysis were included.
in the respective multivariable analysis, with an exclusion of parameters with collinearity. \( p < 0.05 \) was considered statistically significant. SPSS Statistics (version 23; IBM, Armonk, NY, USA) was used for all statistical analyses.

**RESULTS**

**Study population**

Out of all 225 consecutive curative-intent surgeries performed for iCCA (\( n = 112 \)) and pCCA (\( n = 113 \)), 189 patients (iCCA = 86, pCCA = 103) met the predefined inclusion and exclusion criteria. Patient characteristics and perioperative outcome data of the cohort were, in part, reported previously\(^{[14,15,25,26]} \) (Table 1).

Median time between the CT imaging used for segmentation and liver resection was 2 weeks (range, 0–12 weeks). The final study population was composed of 108 men (57%) and 81 women (43%), with a mean age of 65 (SD, 11) years. Textbook outcome was achieved in 41 (48%) patients with iCCA and 34 (33%) patients with pCCA. Median follow-up was 24 months (25 for patients with iCCA, 22 for patients with pCCA). DFS was 10 months in patients with iCCA and 39 months in patients with pCCA, with 54 (63%) patients with iCCA and 41 (40%) patients with pCCA recurring during the follow-up period. Median OS was 30 months and 29 months for patients with iCCA and pCCA, respectively, and thus slightly different in this subcohort (\( n = 189 \)) from the overall cohort (\( n = 225 \); 25 months for iCCA and 33 months for pCCA). During the observation period, 63% (56/86) of patients with iCCA and 72% (70/103) with pCCA died. Detailed patient characteristics, and perioperative outcome are outlined in Table 1.

**BC features in iCCA**

In patients with iCCA, the median SMI was 50.3 cm\(^2/m^2\) (range, 48.3 cm\(^2/m^2\)) for male and 42.4 cm\(^2/m^2\) (range, 32.4 cm\(^2/m^2\)) for female patients. The median SM-RA was 34.5 HU (range, 53.4 HU) for men and 30.1 HU (range, 37.1 HU) for women. Median VFA values were 202.1 cm\(^2\) (range, 505 cm\(^2\)) for men and 78.0 cm\(^2\) (range, 352 cm\(^2\)) for women. For patients with iCCA, 49% (42/86) had a BMI > 25 kg/m\(^2\) (overweight/obese), 33% (28/86) were classified as sarcopenic, and 66% (57/86) had SM-RA values indicative of myosteatosis. Visceral obesity was noted in 56% (48/86) of patients, while the incidence of sarcopenic obesity was 11% (9/86) (Table 2).

**BC and outcome in iCCA**

None of the BC pathologies correlated with pathological characteristics (lymph node positivity or lymphovascular, vascular, or perineural invasion) or postoperative complications, as assessed by the incidence of intraoperative transfusions, 90-day CD \( \geq 3b \) complications, 90-day CCI and 90-day mortality, intensive care unit (ICU) and hospital stay, as well as PHLF (Table S1). BMI \( \geq 25 \) kg/m\(^2\), sarcopenia, and myosteatosis (Table 3; Figure 2) as well as the simultaneous presence of sarcopenia and myosteatosis (data not shown) did not correlate with DFS or OS. When stratifying SMI (sarcopenia), SM-RA (myosteatosis), and VFA in quartiles, no survival trend was observed in any of

| Body composition parameter | Intrahepatic CCA (\( n = 86 \)) | Perihilar CCA (\( n = 103 \)) |
|-----------------------------|-------------------------------|-------------------------------|
| BMI (kg/m\(^2\))            |                               |                               |
| <25 (underweight/normal)    | 44 (51.2)                     | 52 (50.5)                     |
| \( \geq 25 \) (overweight/obese) | 42 (48.8)           | 51 (49.5)                     |
| Sarcopenia (skeletal muscle mass, SMI) | No                 | 57 (66.3)                     |
|                              | Yes                           | 28 (32.6)                     |
| Myosteatosis (SM-RA)        | No                            | 29 (33.7)                     |
|                              | Yes                           | 57 (66.3)                     |
| Visceral obesity (VFA)      | No                            | 38 (44.2)                     |
|                              | Yes                           | 48 (55.8)                     |
| Sarcopenic obesity          | No                            | 77 (89.5)                     |
|                              | Yes                           | 9 (10.5)                      |

Note: Data presented as n (%). Definitions of body composition features are as follows: BMI, weight (kg)/height\(^2\) (m\(^2\)); sarcopenia, SMI < 41 cm\(^2/m^2\) in women and <43 cm\(^2/m^2\) in men with BMI < 25 kg/m\(^2\), and <53 cm\(^2/m^2\) in men with BMI \( \geq 25 \) kg/m\(^2\); myosteatosis, <41 HU for patients with BMI < 24.9 kg/m\(^2\) and <33 HU for patients with BMI \( \geq 25 \) kg/m\(^2\); visceral obesity, VFA \( \geq 100 \) cm\(^2\); sarcopenic obesity, BMI \( \geq 25 \) kg/m\(^2\) and SMI \( \leq 38.5 \) cm\(^2/m^2\) in women and \( \leq 32.4 \) cm\(^2/m^2\) in men, as described\(^{[18]} \).

Abbreviations: BMI, body mass index; CCA, cholangiocarcinoma; SMI, skeletal muscle index; SM-RA, skeletal muscle radiation attenuation; VFA, visceral fat area.
the quartile groups (Figure S1). Sex-specific analysis of sarcopenia, myosteatosis, and visceral obesity did not yield significant results for DFS and OS (data not shown). While visceral obesity did not correlate with DFS and OS, the presence of sarcopenic obesity was a predictor of shorter OS in patients with iCCA. As such, the nine patients with sarcopenic obesity had a median OS of 11 months compared to 31 months median OS in the 77 patients without sarcopenic obesity ($p = 0.002$ (Table 3; Figure 2). The total number of events for patients with and without sarcopenic obesity was eight and 48, the 1-year mortality rate was 55.6% (5/9) and 22% (17/77), and the 5-year mortality rate was 88.9% (8/9) and 61% (47/77), respectively.

In multivariable Cox regression analysis, including all respective significant predictors of DFS and OS from univariable analysis (Table 4), sarcopenic obesity did not reach a significant independent predictive effect for...

### Table 3: Univariable analysis of DFS and OS by body composition in iCCA and pCCA

| Characteristic                              | Median DFS (95% CI) | HR (95% CI) | p value$^a$ | Median OS (95% CI) | HR (95% CI) | p value$^a$ |
|--------------------------------------------|---------------------|-------------|-------------|---------------------|-------------|-------------|
| **iCCA (n = 86)**                          |                     |             |             |                     |             |             |
| Overweight/obesity, BMI (kg/m$^2$)         |                     |             |             |                     |             |             |
| No                                         | 10 (6.1–13.9)       | 0.408       | 31 (18.4–43.6) | 0.182               |
| Yes                                        | 8 (2.6–13.4)        | 0.753       | 25 (14.2–35.8)  | 0.336               |
| Reduced skeletal muscle mass (sarcopenia, SMI) |             |             |             |                     |             |             |
| No                                         | 8 (4.9–11.1)        | 0.280       | 29 (11.5–46.5)  | 0.591               |
| Yes                                        | 12 (8.3–15.7)       | 0.280       | 30 (18.2–41.8)  | 0.591               |
| Myosteatosis (SM-RA)                       |                     |             |             |                     |             |             |
| No                                         | 8 (6.8–9.2)         | 0.400       | 32 (24.2–39.8)  | 0.707               |
| Yes                                        | 12 (7.8–16.2)       | 0.400       | 22 (13.7–30.3)  | 0.707               |
| Visceral obesity (VFA)                     |                     |             |             |                     |             |             |
| No                                         | 10 (6.9–13.1)       | 0.330       | 31 (21.5–40.5)  | 1.002               |
| Yes                                        | 11 (0.0–29.0)       | 0.330       | 11 (0.0–28.5)   | 1.002               |
| Sarcopenic obesity                          |                     |             |             |                     |             |             |
| No                                         | 10 (6.9–13.1)       | 0.330       | 31 (21.5–40.5)  | 1.002               |
| Yes                                        | 11 (0.0–29.0)       | 0.330       | 11 (0.0–28.5)   | 1.002               |
| **pCCA (n = 103)**                         |                     |             |             |                     |             |             |
| Overweight/obesity BMI, kg/m$^2$            |                     |             |             |                     |             |             |
| No                                         | 40 (11.3–68.7)      | 0.696       | 31 (15.3–46.7)  | 0.845               |
| Yes                                        | 31 (0.0–64.6)       | 0.696       | 28 (13.2–42.8)  | 0.845               |
| Reduced skeletal muscle mass (sarcopenia, SMI) |             |             |             |                     |             |             |
| No                                         | 40 (9.5–70.5)       | 0.757       | 31 (12.4–49.6)  | 0.813               |
| Yes                                        | 36 (0.0–73.2)       | 0.757       | 28 (12.5–43.5)  | 0.813               |
| Myosteatosis (SM-RA)                       |                     |             |             |                     |             |             |
| No                                         | 40 (15.7–64.3)      | 0.902       | 24 (14.5–33.5)  | 0.985               |
| Yes                                        | 36 (5.0–67.0)       | 0.902       | 31 (23.9–38.1)  | 0.985               |
| Visceral obesity (VFA)                     |                     |             |             |                     |             |             |
| No                                         | n.a.                | 0.131       | 50 (9.5–90.5)   | 0.072               |
| Yes                                        | 29 (3.2–54.8)       | 0.131       | 20 (6.8–33.2)   | 0.072               |
| Sarcopenic obesity                         |                     |             |             |                     |             |             |
| No                                         | 39 (8.0–70.0)       | 0.812       | 29 (17.3–40.7)  | 0.801               |
| Yes                                        | 55 (0.0–111.2)      | 0.812       | 29 (11.7–46.3)  | 0.801               |

Note: Definitions of body composition features are as follows: BMI, weight (kg)/height$^2$ (m$^2$); sarcopenia, SMI < 41 cm$^2$/m$^2$ in women and <43 cm$^2$/m$^2$ in men with BMI < 25 kg/m$^2$, and <53 cm$^2$/m$^2$ in men with BMI ≥ 25 kg/m$^2$; myosteatosis, <41 HU for patients with BMI < 24.9 kg/m$^2$ and <33 HU for patients with BMI ≥ 25 kg/m$^2$; visceral obesity, VFA ≥ 100 cm$^2$; sarcopenic obesity, BMI > 25 kg/m$^2$ and SMI ≤ 38.5 cm$^2$/m$^2$ in women and ≤52.4 cm$^2$/m$^2$ in men, as described.\(^{18}\)

Abbreviations: BMI, body mass index; CCA, cholangiocarcinoma; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; iCCA, intrahepatic cholangiocarcinoma; OS, overall survival; pCCA, perihilar cholangiocarcinoma; SMI, skeletal muscle index; SM-RA, skeletal muscle radiation attenuation; VFA, visceral fat area.

$^a$Based on log-rank test. $p < 0.05$ is significant.
OS (HR, 1.833; p = 0.471). Instead, only UICC stage III/IV (HR, 3.715; p = 0.037) was confirmed as an independent predictor of shortened DFS, while lymphovascular invasion (HR, 3.706; p = 0.036) was an independent predictor of shortened OS.

**BC features in pCCA**

In patients with pCCA, the median SMI was 51.7 cm²/m² (range, 46.0 cm²/m²) in men and 40.4 cm²/m² (range, 31.4 cm²/m²) in women. The median SM-RA was 35.6 HU (range, 36.9 HU) for men and 30.0 HU (range, 36.2 HU) for women. Median VFA values were 171 cm² (range, 449 cm²) for men and 105 cm² (range, 275 cm²) for women. No significant difference in SMI, SM-RA, or VFA values was noted between the two CCA entities (analysis split by sex). For patients with pCCA, 50% (51/103) were considered overweight/obese based on their BMI, 39% (40/103) were considered sarcopenic, and 66% (68/103) were myosteatotic. Visceral obesity was present in 67% (69/103) of patients, and sarcopenic obesity was found in 17% of patients (17/103) (Table 2).

**BC and outcome in pCCA**

In pCCA, only BMI correlated with postoperative complications. Patients with BMI < 25 kg/m² had a higher incidence of PHLF (16/52, 34.5% for BMI < 25 kg/m² versus 5/51, 9.8% for BMI≥25 kg/m²), while patients with BMI≥25 kg/m² displayed more frequent 90-day ≥CD3b complications (28/51, 55% versus 18/53, 35%) compared to patients with BMI < 25 kg/m² (Table S1). BMI, sarcopenia, myosteatosis, visceral obesity, presence of sarcopenia and myosteatosis (data not shown), and sarcopenic obesity did not correlate significantly with DFS or OS; there was a nonsignificant trend of patients with visceral obesity toward shorter OS (median OS, 20 months versus 50 months in patients without visceral obesity; p = 0.072) (Table 3; Figure 3). A nonsignificant trend toward longer DFS in patients with the lowest quartile SM-RA was noted (p = 0.087; Figure S2). Sex-specific analysis of the association between sarcopenia, myosteatosis, and visceral obesity with DFS and OS was not significant (data not shown).

In multivariable analysis, including the significant results from univariable analysis (Table 5), preoperative
### Table 4
Univariable analysis of DFS and OS by clinicopathological characteristics in iCCA

| Characteristic | n (%) | Median DFS (95% CI) | HR (95% CI) | p value* | Median OS (95% CI) | HR (95% CI) | p value* |
|----------------|-------|---------------------|-------------|----------|---------------------|-------------|----------|
| Sex            |       |                     |             |          |                     |             |          |
| Male           | 37 (43.5) | 10 (4.9–15.1) | 0.792 | 0.658 | 22 (6.0–38.0) | 0.658 |
| Female         | 48 (56.5) | 10 (6.2–13.8) | 0.197 | 0.010 | 30 (18.2–41.8) | 0.010 |
| Age, years     |       |                     |             |          |                     |             |          |
| ≤65            | 40 (47.1) | 8 (4.3–11.7) | 0.644 | 0.986 | 22 (14.3–29.7) | 0.986 |
| >65            | 45 (52.9) | 11 (5.6–16.4) | 0.127 | 0.548 | 30 (20.8–39.2) | 0.548 |
| Cholangitis    |       |                     |             |          |                     |             |          |
| No             | 77 (90.6) | 9 (6.2–11.8) | 0.109 | 0.239 | 29 (20.6–37.4) | 0.239 |
| Yes            | 8 (9.4) | n.a. | n.a. | n.a. | n.a. | n.a. |
| PVE            |       |                     |             |          |                     |             |          |
| No             | 77 (90.6) | 11 (8.9–13.1) | 0.644 | 0.986 | 22 (14.3–29.7) | 0.986 |
| Yes            | 8 (9.4) | 9 (5.2–12.8) | 0.644 | 0.986 | 30 (20.8–39.2) | 0.986 |
| EBD            |       |                     |             |          |                     |             |          |
| No             | 71 (83.5) | 8 (5.6–10.4) | 0.127 | 0.548 | 36 (10.6–61.4) | 0.548 |
| Yes            | 14 (16.5) | 26 (3.6–48.4) | 0.127 | 0.548 | 29 (20.2–37.8) | 0.548 |
| Albumin, g/L   |       |                     |             |          |                     |             |          |
| ≤42            | 28 (32.9) | 8 (3.9–12.2) | 0.360 | 0.413 | 20 (0.0–45.8) | 0.413 |
| >42            | 56 (65.9) | 12 (7.6–16.4) | 0.360 | 0.413 | 31 (22.0–40.0) | 0.413 |
| AST, U/L       |       |                     |             |          |                     |             |          |
| ≤40            | 49 (57.6) | 13 (4.3–21.7) | 0.551 | 0.638 | 25 (12.5–37.5) | 0.638 |
| >40            | 35 (41.2) | 8 (5.5–10.5) | 0.551 | 0.638 | 36 (11.8–60.2) | 0.638 |
| ALT, U/L       |       |                     |             |          |                     |             |          |
| ≤40            | 39 (45.9) | 15 (6.5–23.5) | 0.767 | 0.900 | 32 (13.5–50.5) | 0.900 |
| >40            | 45 (52.9) | 8 (3.7–12.3) | 0.767 | 0.900 | 25 (14.1–35.9) | 0.900 |
| GGT, U/L       |       |                     |             |          |                     |             |          |
| ≤100           | 35 (41.2) | 10 (5.9–14.1) | 0.851 | 0.917 | 29 (19.3–38.7) | 0.917 |
| >100           | 49 (57.6) | 11 (6.3–15.6) | 0.851 | 0.917 | 32 (10.3–53.7) | 0.917 |
| Bilirubin, mg/dL|     |                     |             |          |                     |             |          |
| ≤1             | 66 (77.6) | 11 (6.6–15.4) | 0.618 | 0.820 | 30 (20.1–39.9) | 0.820 |
| >1             | 17 (20.0) | 8 (6.4–9.6) | 0.618 | 0.820 | 50 (0.1–100.0) | 0.820 |
| Alkaline phosphatase, U/L |         |                     |             |          |                     |             |          |
| ≤100           | 26 (30.6) | 12 (5.6–18.4) | 0.688 | 0.622 | 22 (19.0–25.0) | 0.622 |
| >100           | 58 (68.2) | 10 (7.2–12.8) | 0.688 | 0.622 | 31 (23.5–38.5) | 0.622 |
| Platelet count, 1/mL |    |                     |             |          |                     |             |          |
| ≤200           | 24 (28.2) | 12 (1.7–22.3) | 0.934 | 0.066 | 20 (3.0–37.0) | 0.066 |
| >200           | 60 (70.6) | 10 (7.0–13.0) | 0.934 | 0.066 | 32 (21.3–42.7) | 0.066 |
| INR            |       |                     |             |          |                     |             |          |
| ≤1             | 46 (54.1) | 10 (4.8–15.2) | 0.319 | 0.912 | 25 (13.4–36.6) | 0.912 |
| >1             | 38 (44.7) | 9 (1.8–12.5) | 0.319 | 0.912 | 30 (17.6–46.4) | 0.912 |
| Hemoglobin, g/dL|     |                     |             |          |                     |             |          |
| ≤12            | 21 (24.7) | 11 (2.8–19.2) | 0.333 | 0.068 | 19 (0.0–43.5) | 0.068 |
| >12            | 63 (74.1) | 10 (5.4–14.6) | 0.333 | 0.068 | 32 (21.7–42.3) | 0.068 |
| CRP, mg/L      |       |                     |             |          |                     |             |          |
| ≤10            | 46 (51.1) | 11 (5.8–16.2) | 0.108 | 0.061 | 31 (17.9–44.1) | 0.061 |
| >10            | 38 (44.7) | 8 (4.3–11.7) | 0.108 | 0.061 | 29 (14.0–44.0) | 0.061 |
### TABLE 4 (Continued)

| Characteristic                  | n (%)       | Median DFS (95% CI) | HR (95% CI) | p value<sup>a</sup> | Median OS (95% CI) | HR (95% CI) | p value<sup>a</sup> |
|--------------------------------|-------------|---------------------|-------------|--------------------|--------------------|-------------|--------------------|
| **Operative time, minutes**    |             |                     |             |                    |                    |             |                    |
| ≤300                           | 49 (57.6)   | 11 (7.9–14.1)       | 0.884       |                    | 25 (16.9–33.1)     | 0.958       |                    |
| >300                           | 36 (42.4)   | 8 (6.4–9.6)         |             |                    | 32 (21.5–42.5)     |             |                    |
| **Blood transfusions**         |             |                     |             |                    |                    |             |                    |
| No                             | 60 (70.6)   | 11 (6.2–15.8)       | 0.402       |                    | 29 (18.5–39.5)     | 0.212       |                    |
| Yes                            | 25 (29.4)   | 8 (0.2–15.8)        |             |                    | 30 (11.4–48.6)     |             |                    |
| **FFP transfusions**           |             |                     |             |                    |                    |             |                    |
| No                             | 54 (63.5)   | 10 (7.0–13.0)       | 0.805       |                    | 29 (21.1–36.9)     | 0.718       |                    |
| Yes                            | 31 (36.5)   | 8 (1.1–14.9)        |             |                    | 32 (12.3–51.7)     |             |                    |
| **R status**                   |             |                     |             |                    |                    |             |                    |
| R0                             | 62 (72.9)   | 10 (6.2–13.8)       | 0.475       |                    | 31 (16.3–45.7)     | 0.163       |                    |
| R1/Rx                          | 18 (21.2)   | 8 (5.8–10.3)        |             |                    | 22 (2.4–41.6)      |             |                    |
| **Microvascular invasion**     |             |                     |             |                    |                    |             |                    |
| No                             | 46 (54.1)   | 8 (4.0–12.0)        | 0.236       |                    | 31 (13.9–48.1)     | 0.645       |                    |
| Yes                            | 32 (37.6)   | 10 (7.0–13.0)       |             |                    | 30 (18.5–41.5)     |             |                    |
| **Perineural invasion**        |             |                     |             |                    |                    |             |                    |
| Pn0                            | 22 (25.9)   | 10 (5.7–14.3)       | 0.370       |                    | 36 (25.7–46.3)     | 1           | 0.031              |
| Pn1                            | 17 (20.0)   | 12 (2.6–21.4)       |             |                    | 19 (8.4–29.6)      | 2.354       | (1.041–5.324)      |
| **Lymphovascular invasion**    |             |                     |             |                    |                    |             |                    |
| No                             | 57 (67.1)   | 8 (4.9–11.1)        | 0.367       |                    | 40 (25.2–54.8)     | 1           | 0.000              |
| Yes                            | 21 (24.7)   | 10 (0.6–19.4)       |             |                    | 4 (1.1–6.9)        | 3.929       | (2.158–7.151)      |
| **Tumor grading**              |             |                     |             |                    |                    |             |                    |
| G1/G2                          | 48 (56.5)   | 8 (4.0–12.0)        | 0.708       |                    | 32 (21.3–42.7)     | 0.348       |                    |
| G3/G4                          | 25 (29.4)   | 9 (5.1–12.9)        |             |                    | 20 (0.0–41.6)      |             |                    |
| **Tumor stage (UICC)**         |             |                     |             |                    |                    |             |                    |
| I/II                           | 42 (49.4)   | 18 (9.5–26.5)       | 1           | 0.001              | 45 (26.8–63.2)     | 1           | 0.001              |
| III/IV                         | 33 (38.8)   | 6 (1.5–10.5)        | 2.607 (1.448–4.691) | 16 (4.0–28.0) | 2.597 (1.472–4.581) | |
| **pT category**                |             |                     |             |                    |                    |             |                    |
| pT1–2                          | 71 (83.5)   | 11 (7.9–14.1)       | 0.284       |                    | 30 (17.6–42.4)     | 0.202       |                    |
| pT3–4                          | 12 (14.1)   | 7 (4.1–9.9)         |             |                    | 22 (0.0–57.5)      |             |                    |
| **N category**                 |             |                     |             |                    |                    |             |                    |
| pN0                            | 45 (52.9)   | 12 (3.1–20.9)       | 1           | 0.005              | 45 (28.1–61.9)     | 1           | 0.000              |
| pN1                            | 30 (35.3)   | 6 (2.2–9.8)         | 2.253 (1.241–4.092) | 16 (4.7–27.3) | 2.855 (1.602–5.087) | |
| **Tumor number**               |             |                     |             |                    |                    |             |                    |
| Single                         | 49 (55.1)   | 15 (6.7–23.3)       | 1           | 0.007              | 36 (22.6–49.4)     | 1           | 0.009              |
| Multiple                       | 35 (39.3)   | 8 (7.0–9.0)         | 2.043 (1.182–3.533) | 22 (19.4–24.6) | 1.998 (1.165–3.426) | |
| **Tumor size**                 |             |                     |             |                    |                    |             |                    |
| ≤5 cm                          | 21 (24.4)   | 15 (4.4–25.6)       | 0.058       |                    | 21 (0.0–44.3)      | 0.697       |                    |
| >5 cm                          | 62 (72.1)   | 8 (5.5–10.5)        |             |                    | 30 (23.4–36.6)     |             |                    |
| **ICU time, days**             |             |                     |             |                    |                    |             |                    |
| Mean, SD                       | 3.5±8.6     | 0.923 (0.997–0.930) | 0.923       | 1.041              | (1.019–1.065)      | 0.000       | (Continues)        |
hemoglobin ≤12 g/dL (HR, 2.448; \( p = 0.05 \)) and fresh-frozen plasma transfusions (HR, 3.331; \( p = 0.020 \)) were independent predictors of shortened DFS. Tumor grading 3–4 (HR, 1.930; \( p = 0.045 \)) and CCI > 40 (HR, 3.060; \( p = 0.001 \)) independently predicted OS (Table 6).

**DISCUSSION**

Intrahepatic and perihilar CCA are rare and aggressive malignancies with high rates of recurrence, even after extensive and high-risk major liver resections.\(^{[17]}\) In this study, we analyzed preoperative CT scans to determine the incidence and the prognostic value of BC alterations in a large and homogeneous Western cohort of patients with iCCA and pCCA. The two tumor entities were analyzed separately for all outcome measures due to their inherent differences in prognosis and etiology. Alterations of BC were highly prevalent, with 50% of all patients being overweight or obese, 34% of patients sarcopenic, 66% myosteatotic, 62% displaying visceral obesity, and 14% of the overall cohort with sarcopenic obesity. We saw no relevant association of BC pathologies with pathological markers of aggressive tumor biology or with perioperative outcome parameters. While being overweight, sarcopenic, myosteatotic, or viscera-ally obese was not associated with altered DFS or OS, patients with iCCA with sarcopenic obesity were at an increased risk for inferior OS (11 months survival with sarcopenic obesity compared to 31 months OS in the remaining cohort; HR, 3.193; log-rank \( p = 0.002 \)). This effect was not sustained in the multivariable analysis, possibly due to the relatively low number of patients at risk and events in the sarcopenic obesity group despite the high probability of death (n = 9 patients, eight events).

Our observation that sarcopenia, while not being predictive for the entire cohort, had a relevant prognostic value in a subset of patients who were overweight and obese with iCCA has been similarly noted in patients with pancreatic adenocarcinoma.\(^{[7]}\) The hypothesis that low lean body mass combined with obesity results in lower performance status and lower OS in patients with tumors has been brought forward by Prado et al.\(^{[27]}\) who delineated sarcopenia as an independent risk factor in individuals with obesity with gastrointestinal and pulmonary malignancies. In sarcopenic obesity, two highly prevalent risk factors come together—an aging population and a global obesity epidemic. In this regard, the traditional focus on isolated BMI measurement for the diagnosis of cachexia/muscle wasting is currently evolving toward more detailed assessments, including functional tests and imaging techniques.\(^{[28]}\) The isolated analysis of BMI in patients with cancer, including patients with gastrointestinal malignancies, has shaped the so-called obesity paradox, the observation that while patients who are overweight or class I obese (BMI, 30 to <35 kg/m\(^2\)) are at a higher risk for cancer, their risk for overall mortality is lower than in normal-weight patients.\(^{[29,30]}\) This phenomenon can be explained by, first, a BMI bias, namely, that BMI does not distinguish muscle mass and quality on one side and adipose mass and distribution on the other; second, by the fact that patients who are overweight and obese typically have higher overall muscle mass.\(^{[31]}\) Approximately one half

---

**TABLE 4** (Continued)

| Characteristic   | n (%) | Median DFS (95% CI) | HR (95% CI) | \( p \) value\(^a\) | Median OS (95% CI) | HR (95% CI) | \( p \) value\(^a\) |
|------------------|-------|---------------------|-------------|----------------------|---------------------|-------------|----------------------|
| Hospitalization, days | | | | | | | |
| Mean, SD        | 18.1 ± 14.5 | 1.016 (0.998–1.035) | 0.087 | | 1.029 (1.013–1.045) | 0.000 |
| CCI              | | | | | | | |
| ≤40             | 54 (63.5) | 11 (7.2–14.8) | 0.437 | 32 (24.3–39.7) | 0.059 |
| >40             | 31 (36.5) | 8 (5.0–11.0) | 2.543 (1.350–4.789) | 0.002 | 22 (12.2–31.8) | 0.953 |
| Adjuvant therapy| No    | 33 (38.8) | 27 (1.4–52.6) | 1 | 0.000 | 22 (12.2–31.8) | 0.953 |
| Yes             | 50 (58.8) | 7 (5.7–8.3) | 22 (1.4–52.6) | 0.000 | 22 (12.2–31.8) | 0.953 |
| Tumor recurrence| No    | 29 (34.1) | 58 (0.0–149.4) | 0.269 | | |
| Yes             | 54 (63.5) | 27 (19.7–34.2) | 0.269 | | | |

Note: The cohort was dichotomized at the median age of the cohort.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CCI, comprehensive complication index; CI, confidence interval; CRP, C-reactive protein; DFS, disease-free survival; EBD, endoscopic biliary drainage; FFP, fresh-frozen plasma; GGT, gamma-glutamyltransferase; HR, hazard ratio; iCCA, intrahepatic cholangiocarcinoma; ICU, intensive care unit; INR, international normalized ratio; OS, overall survival; PBD, percutaneous biliary drainage; pT, pathological tumor stage; PVE, portal vein embolization; UICC, Union Internationale Contre le Cancer.
\(^a\)Based on log-rank test. \( p < 0.05 \) is significant.
of our study population was overweight or obese at the time of operation, making it unlikely that these patients would routinely attract clinical attention as being malnourished. Thus, raising the attention to muscle wasting that is masked by excessive adipose tissue may allow for prognostic patient selection and risk stratification as well as facilitate therapeutic interventions, such as nutritional counseling and support and physical prehabilitation.[28] The routine assessment of BC has been incorporated in the 2019 European Association for the Study of the Liver guidelines on clinical nutrition in chronic liver disease, with a recommendation to include sarcopenia evaluation, ideally on available CT scans, into the nutritional assessment.[8] Based on the data from this and future studies, a similar evaluation for sarcopenic obesity may be warranted in patients with iCCA.

Reasons for sarcopenia and sarcopenic obesity in the general population are largely age and lifestyle associated. Nerve cell reduction, decreased concentrations of anabolic hormones (growth hormone, testosterone, insulin-like growth factor), impaired regeneration, as well as decreased and dysfunctional protein synthesis are typical hallmarks of aging.[32] Additionally, patients with cancer exhibit a hypermetabolic state with a systemic inflammatory response that promotes nuclear factor kappa B pathway-mediated muscle degradation and cachexia.[33] Similarly, patients with obesity also have higher levels of inflammatory cytokines, such as interleukin (IL)-6, C-reactive protein, IL-1RA, and soluble IL-6R, and patients with these biochemical changes in turn have lower muscle strength.[34] Thus, sarcopenic obesity in patients with cancer can be viewed as a condition that arises against the background of a severely dysregulated multifactorial metabolic deregulation and a systemic inflammatory response. A recent murine CCA model of targeted Kirsten rat sarcoma viral oncogene homolog (KRAS) activation and loss of p53 recapitulated these hallmarks of sarcopenia and inflammation in the absence of weight loss.[35]

Few studies have examined the role of BC in CCA. A single-center study in surgically treated pCCA suggested an independent prognostic value of sarcopenia and low bone mineral density.[36] In a mixed cohort of 117 patients with curative or palliative regimens for iCCA, pCCA, dCCA, or gallbladder carcinoma, sarcopenia and myosteatosis were independent prognostic
# Table 5

Univariable analysis of DFS and OS by clinicopathological characteristics in pCCA

| Characteristic | n (%) | Median DFS (95% CI) | HR | p value<sup>a</sup> | Median OS (95% CI) | HR | p value<sup>a</sup> |
|----------------|-------|---------------------|----|---------------------|---------------------|----|---------------------|
| Sex            |       |                     |    |                     |                     |    |                     |
| Male           | 71 (68.9) | 39 (12.6–65.4)     | 0.642 | 31 (18.6–43.4) | 0.332 |
| Female         | 32 (31.1) | 26 (0.0–84.5)      | 0.789 | 20 (6.1–33.9)    | 0.686 |
| Age, years     |       |                     |    |                     |                     |    |                     |
| ≤65            | 44 (42.7) | 40 (12.6–67.4)     | 0.696 | 31 (15.3–46.7) | 0.845 |
| >65            | 58 (56.3) | 37 (0.0–77.3)      | 0.283 | 28 (13.2–42.8)   | 0.206 |
| BMI, kg/m²     |       |                     |    |                     |                     |    |                     |
| ≤25            | 52 (50.5) | 40 (11.3–68.7)     | 0.696 | 31 (15.3–46.7) | 0.845 |
| >25            | 51 (49.5) | 31 (0.0–64.6)      | 0.283 | 28 (13.2–42.8)   | 0.206 |
| Cholangitis    |       |                     |    |                     |                     |    |                     |
| No             | 63 (61.2) | 31 (21.3–40.7)     | 0.098 | 31 (14.4–47.6) | 0.089 |
| Yes            | 36 (35.0) | 61 (n.a.)           | 0.055 | 28 (17.9–38.1) | 0.089 |
| PVE            |       |                     |    |                     |                     |    |                     |
| No             | 44 (42.7) | 40 (12.5–67.5)     | 0.998 | 31 (21.6–40.4) | 0.746 |
| Yes            | 59 (57.3) | 36 (0.0–83.3)      | 0.907 | 25 (9.0–41.0)    | 0.711 |
| EBD            |       |                     |    |                     |                     |    |                     |
| No             | 21 (20.4) | n.a.                | 0.055 | n.a.              | 0.089 |
| Yes            | 82 (79.6) | 36 (13.1–58.9)     | 0.055 | 28 (17.9–38.1) | 0.089 |
| PTCD           |       |                     |    |                     |                     |    |                     |
| No             | 79 (76.7) | 39 (9.3–68.7)      | 0.907 | 31 (22.8–39.2) | 0.711 |
| Yes            | 23 (22.3) | 36 (0.0–59.3)      | 0.907 | 29 (0.0–59.3)    | 0.711 |
| Albumin, g/L   |       |                     |    |                     |                     |    |                     |
| ≤42            | 68 (66.0) | 29 (7.0–51.0)      | 0.365 | 20 (7.4–32.6) | 0.453 |
| >42            | 35 (34.0) | 55 (25.5–84.5)     | 0.365 | 38 (27.2–48.7) | 0.453 |
| AST, U/L       |       |                     |    |                     |                     |    |                     |
| ≤40            | 37 (35.9) | 84 (20.7–147.3)    | 0.315 | 31 (12.2–49.8) | 0.788 |
| >40            | 66 (64.1) | 31 (5.5–56.5)      | 0.315 | 29 (19.5–38.5) | 0.788 |
| ALT, U/L       |       |                     |    |                     |                     |    |                     |
| ≤40            | 18 (17.5) | 40 (0.0–84.0)      | 0.767 | 23 (8.4–37.6) | 0.438 |
| >40            | 85 (82.5) | 39 (10.1–67.9)     | 0.767 | 31 (18.0–44.1) | 0.438 |
| GGT, U/L       |       |                     |    |                     |                     |    |                     |
| ≤100           | 8 (7.8)  | 61 (13.1–108.9)    | 0.507 | 32 (0.0–70.8) | 0.838 |
| >100           | 95 (92.2) | 37 (10.2–63.8)     | 0.507 | 29 (18.1–39.9) | 0.838 |
| Bilirubin, mg/dL|      |                     |    |                     |                     |    |                     |
| ≤1             | 45 (43.7) | 84 (25.2–142.8)    | 0.298 | 32 (27.1–36.9) | 0.513 |
| >1             | 57 (55.3) | 36 (4.5–67.5)      | 0.298 | 25 (8.4–42.0)   | 0.513 |
| Alkaline phosphatase, U/L | | n.a. | 0.239 | n.a. | 0.113 |
| ≤100           | 4 (3.9)  | n.a.                | 0.239 | n.a.             | 0.113 |
| >100           | 99 (96.1) | 37 (9.6–64.4)      | 0.239 | 28 (17.8–38.2) | 0.113 |
| Platelet count, 1/nL | | n.a. | 0.525 | 4 (0.5–7.5) | 0.462 |
| ≤200           | 13 (12.6) | n.a.                | 0.525 | n.a.             | 0.462 |
| >200           | 90 (87.4) | 39 (11.0–67.0)     | 0.525 | 31 (23.1–38.9) | 0.462 |
| INR            |       |                     |    |                     |                     |    |                     |
| ≤1             | 38 (36.9) | 61 (n.a.)           | 0.160 | 50 (22.8–77.2) | 0.141 |
| >1             | 65 (63.1) | 31 (8.7–53.3)      | 0.160 | 24 (8.0–39.6)   | 0.141 |
| Characteristic                  | n (%)     | Median DFS (95% CI)  | HR (95% CI) | p value  | Median OS (95% CI) | HR (95% CI) | p value  |
|--------------------------------|-----------|----------------------|-------------|----------|-------------------|-------------|----------|
| Hemoglobin, g/dL               |           |                      |             |          |                   |             |          |
| ≤12                            | 38 (36.9) | 14 (6.1–21.9)        | 3.022 (1.621–5.633) | 0.000    | 15 (5.9–24.1)     | 1.753 (1.093–2.811) | 0.016    |
| >12                            | 65 (63.1) | 84 (35.0–133.0)      | 1           |          | 32 (21.3–42.7)    | 1           |          |
| CRP, mg/L                      |           |                      |             |          |                   |             |          |
| ≤10                            | 42 (40.8) | 61 (n.a.)            | 0.243       |          | 32 (21.7–36.9)    | 1           | 0.188    |
| >10                            | 61 (59.2) | 36 (20.8–51.2)       | 1           |          | 23 (5.0–41.0)     | 1           |          |
| Operative time, minutes        |           |                      |             |          |                   |             |          |
| ≤360                           | 30 (29.1) | 18 (0.0–56.3)        | 0.914       |          | 31 (0.0–74.1)     | 1           | 0.176    |
| >360                           | 73 (70.9) | 39 (12.0–66.0)       | 1           |          | 29 (15.8–42.1)    | 1           |          |
| Blood transfusions             |           |                      |             |          |                   |             |          |
| No                             | 56 (54.4) | 84 (43.1–124.9)      | 1           | 0.002    | 54 (21.3–86.7)    | 1           | 0.002    |
| Yes                            | 47 (45.6) | 14 (3.6–24.4)        | 2.520 (1.353–4.692) | 0.016    | 12 (6.6–17.4)     | 2.057 (1.288–3.288) |          |
| FFP                            |           |                      |             |          |                   |             |          |
| No                             | 39 (37.9) | n.a.                 | 1           | 0.004    | 69 (22.8–115.2)   | 1           | 0.002    |
| Yes                            | 64 (62.1) | 29 (9.9–48.1)        | 2.662 (1.328–5.333) |          | 15 (4.1–25.9)     | 2.163 (1.288–3.635) |          |
| R status                       |           |                      |             |          |                   |             |          |
| R0                             | 78 (75.7) | 55 (17.1–92.9)       | 0.475       |          | 31 (17.8–44.2)    | 1           | 0.196    |
| R1/Rx                          | 24 (23.3) | 36 (0.2–71.8)        | 18 (1.2–34.8) |          |                   |             |          |
| MVI                            |           |                      |             |          |                   |             |          |
| No                             | 71 (68.9) | 84 (21.9–146.1)      | 0.114       |          | 38 (25.9–50.1)    | 1           | 0.334    |
| Yes                            | 26 (25.2) | 29 (12.9–45.1)       | 18 (0.0–38.0) |          |                   |             |          |
| Perineural invasion            |           |                      |             |          |                   |             |          |
| Pn0                            | 15 (14.6) | n.a.                 | 0.241       |          | 69 (11.9–126.1)   | 1           | 0.120    |
| Pn1                            | 68 (66.0) | 36 (22.0–50.0)       | 20 (2.8–37.2) |          |                   |             |          |
| LVI                            |           |                      |             |          |                   |             |          |
| No                             | 74 (71.8) | 61 (33.5–88.5)       | 1           | 0.004    | 41 (23.6–58.4)    | 1           | 0.005    |
| Yes                            | 21 (20.4) | 15 (7.2–22.8)        | 2.810 (1.342–5.883) |          | 12 (0.1–23.9)     | 2.190 (1.241–3.866) |          |
| Tumor grading                  |           |                      |             |          |                   |             |          |
| G1/G2                          | 74 (71.8) | 84 (19.2–148.8)      | 1           | 0.026    | 41 (23.5–58.5)    | 1           | 0.000    |
| G3/G4                          | 24 (23.3) | 10 (0.0–51.4)        | 2.288 (1.073–4.877) |          | 6 (1.2–10.8)      | 2.937 (1.738–4.964) |          |
| Tumor stage UICC               |           |                      |             |          |                   |             |          |
| I/II                           | 42 (40.8) | 84 (28.0–140.0)      | 1           | 0.016    | 54 (33.1–74.9)    | 1           | 0.002    |
| III/IV                         | 60 (58.3) | 29 (5.5–52.5)        | 1.482 (1.066–2.061) |          | 13 (4.5–21.5)     | 2.173 (1.306–3.614) |          |
| pT category                    |           |                      |             |          |                   |             |          |
| pT1–2                          | 66 (64.1) | 55 (16.8–93.2)       | 0.081       |          | 40 (19.7–60.3)    | 1           | 0.001    |
| pT3–4                          | 36 (35.0) | 15 (4.8–25.2)        | 10 (5.0–15.0) |          | 2.145 (1.324–3.474) |          |          |
| N category                     |           |                      |             |          |                   |             |          |
| pN0                            | 57 (55.3) | 84 (30.0–138.2)      | 1           | 0.001    | 50 (28.0–72.0)    | 1           | 0.002    |
| pN1                            | 44 (42.7) | 6 (0.0–37.2)         | 2.790 (1.475–5.276) |          | 13 (2.2–23.8)     | 2.064 (1.271–3.352) |          |

(Continues)
factors for survival while the prognostic value of sarcopenic obesity was not investigated in this heterogeneous cohort.\textsuperscript{37} Similarly, a recent study of 75 palliative CCA cases suggested a prognostic role of both sarcopenia and myosteatosis, as assessed by L3 CT SMI and SM-RA, but without differentiating between CCA subtypes.\textsuperscript{38} In a mixed cohort of 76 patients with intrahepatic and extrahepatic biliary cancer, including gallbladder carcinoma, sarcopenia predicted OS in male patients,\textsuperscript{39} an observation that was not replicated in our cohort. In comparison, our larger cohort of only patients with iCCA and pCCA failed to show a prognostic value of sarcopenia and myostatosis for DFS or OS, potentially due to the absence of distal CCA cases in the cohort. Similarly, in comparison to a palliative cohort, patients undergoing major liver surgery are highly preselected for their functional status, which impairs comparability of our data to studies with patients receiving palliative care.\textsuperscript{37,38}

As with all clinical outcome studies, this analysis has the following potential limitations: first, the retrospective single-center nature of the study requiring prospective multicentric validation; second, the relatively small group of patients at risk for each BC pathology owing to the rarity of the disease and the split analysis for iCCA and pCCA; third, the lack of functional assessment, such as handgrip strength, which would require prospective patient recruitment and may be biased due to preoperative patient selection of patients fit enough to undergo surgery; and fourth, the relatively advanced disease at the time of surgical treatment (e.g., >70% of patients with iCCA were staged as ≥T2). Nevertheless, to our knowledge, the present study comprises the largest and most homogeneous CCA cohort focusing on BC analysis in patients with surgical iCCA and pCCA and the first investigation of sarcopenic obesity in CCA, revealing a potential prognostic value of this specific BC profile for OS in iCCA. We accordingly see added value in extrapolating

| Characteristic | n (%) | Median DFS (95% CI) | HR | \( p \) value\textsuperscript{a} | Median OS (95% CI) | HR | \( p \) value\textsuperscript{a} |
|----------------|-------|---------------------|----|-----------------|-------------------|----|-----------------|
| Tumor number   |       |                     |    |                 |                   |    |                 |
| Single         | 74 (71.8) | 39 (10.6–67.4) | 0.934 |                     | 31 (20.7–41.3) | 0.723 |                 |
| Multiple       | 25 (24.2) | 19 (n.a.) |                     | 18 (4.0–32.1) |                 |       |
| Tumor size     |       |                     |    |                 |                   |    |                 |
| ≤3 cm          | 48 (46.6) | n.a. | 1 | 0.001 | 54 (29.5–78.5) | 1 | 0.005 |
| >3 cm          | 43 (41.7) | 12 (3.0–21.0) | 2.496 (1.286–4.842) |                     | 13 (4.0–22.0) | 2.262 (1.376–3.719) |       |
| ICU time, days | Mean, SD | 6.2 ± 15.4 | 1.010 | (0.978–1.043) |                     | 1.022 (1.011–1.033) |       |
| Hospitalization, days | Mean, SD | 25.8±20.6 | 1.013 (0.997–1.030) | 0.112 |                   | 1.014 (1.002–1.025) | 0.020 |
| CCI            |       |                     |    |                 |                   |    |                 |
| ≤40           | 50 (48.5) | 84 (35.0–133.0) | 1 | 0.015 | 69 (41.4–96.6) | 1 | 0.000 |
| >40           | 61 (59.2) | 17 (0.0–38.8) | 2.130 (1.136–3.994) |                     | 7 (0.0–14.1) | 3.099 (1.890–5.081) |       |
| Adjuvant therapy\textsuperscript{b} |       |                     |    |                 |                   |    |                 |
| No            | 62 (60.2) | 84 (n.a.) | 1 | 0.000 | 25 (0.0–56.2) | 0.204 |       |
| Yes           | 41 (39.8) | 19 (5.5–32.6) | 3.174 (1.617–6.229) |                     | 29 (22.0–36.0) |       |
| Tumor recurrence |     |                     |    |                 |                   |    |                 |
| No            | 60 (58.3) | 60 (15.7–104.3) | 0.003 |                     |       |
| Yes           | 41 (39.8) | 25 (15.0–35.0) |       |                   |       |

Note: The cohort was dichotomized at the median age of the cohort.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CCI, comprehensive complication index; CI, confidence interval; CRP, C-reactive protein; DFS, disease-free survival; EBD, endoscopic biliary drainage; FFP, fresh-frozen plasma; GGT, gamma-glutamyltransferase; HR, hazard ratio; ICU, intensive care unit; INR, international normalized ratio; LVI, lymphovascular invasion; MVI, microvascular invasion; n.a., not applicable; OS, overall survival; PBD, percutaneous biliary drainage; pCCA, perihilar cholangiocarcinoma; PT, pathological tumor stage; PTCD, percutaneous transhepatic cholangiography; PVE, portal vein embolization; UICC, Union Internationale Contre le Cancer.

\textsuperscript{a} (Header row, behind \( p \)): based on log rank test, for continuous variables (ICU stay, Hospital stay) based on Cox regression analysis.

\textsuperscript{b} (Behind adjuvant therapy): all patients receiving at least one cycle of chemotherapy were considered in this category.
BC data from routinely performed CTs in patients with iCCA, with a focus on sarcopenic obesity.

**AUTHOR CONTRIBUTIONS**

Study design by the initiating study team: Zoltan Czigany, Georg Lurje, Ulf Peter Neumann. Data collection and analysis: Sarah Eischet, Isabella Lurje, Zoltan Czigany, Jan Bednarsch, Tom Florian Ulmer, Peter Isfort, Pavel Strnad, Ulf Peter Neumann, Georg Lurje. Image analysis: Sarah Eischet, Zoltan Czigany. Manuscript draft: Isabella Lurje, Zoltan Czigany, Georg Lurje, Sarah Eischet. Further authors substantially contributing to the final version of the manuscript: Sarah Eischet, Isabella Lurje, Jan Bednarsch, Tom Florian Ulmer, Peter Isfort, Christian Trautwein, Frank Tacke, Ulf Peter Neumann, Georg Lurje. The final version of the manuscript was approved by all authors.

**ACKNOWLEDGMENT**

The visual abstract was created using Biorender.com. Open Access funding enabled and organized by Projekt DEAL.

**FUNDING INFORMATION**

Faculty of Medicine, RWTH Aachen University, START Program, Grants: #136/17 and #23/19; Faculty of Medicine, RWTH Aachen University Clinician Scientist Program; Excellence Initiative of the German federal and state governments, Grants G: [DE-82] ZUK2-SF-OPSF443; This study had no involvement by the funders in study design, data collection, data analysis, manuscript preparation, or decision to publish.

**CONFLICT OF INTEREST**

The authors of this manuscript have no conflict of interest to declare.

**ETHICAL APPROVAL**

This study was conducted in accordance with the current version of the Declaration of Helsinki and good clinical practice guidelines (International Conference on Harmonization, Good Clinical Practice). Approval was granted by the institutional review board (EK 341/21).

**ORCID**

Zoltan Czigany https://orcid.org/0000-0003-0373-3210
Georg Lurje https://orcid.org/0000-0001-9674-0756

---

**TABLE 6** Multivariable Cox regression analysis of prognostic factors for disease-free and overall survival in iCCA and pCCA

| Prognostic factor       | Disease-free survival | Overall survival |
|-------------------------|-----------------------|-----------------|
|                         | Hazard ratio (95% CI) | p value<sup>a</sup> | Hazard ratio (95% CI) | p value<sup>a</sup> |
| iCCA                    |                       |                 |                         |                 |
| Perineural invasion     | n.s.<sup>b</sup>     | 1.378 (0.456–4.164) | 0.570                   |
| Lymphovascular invasion | n.s.<sup>b</sup>     | 3.706 (1.083–12.573) | 0.036                   |
| Lymph node invasion     | 1.503 (0.439–5.142)   | 0.516           | 0.901 (0.116–11.605)   | 0.901           |
| UICC stage III/IV       | 3.715 (1.081–12.765)  | 0.037           | 1.652 (0.185–14.730)   | 0.653           |
| Sarcopenic obesity      | n.s.<sup>b</sup>     | 1.833 (0.353–9.501) | 0.471                   |
| pCCA                    |                       |                 |                         |                 |
| Hemoglobin ≤ 12 g/dL    | 2.448 (1.000–5.990)   | 0.050           | 0.940 (0.471–1.876)   | 0.860           |
| Blood transfusions      | 1.443 (0.533–3.906)   | 0.470           | 1.139 (0.539–2.409)   | 0.733           |
| FFP transfusions        | 3.331 (1.207–9.194)   | 0.020           | 1.510 (0.700–3.256)   | 0.293           |
| Lymphovascular invasion | 1.630 (0.682–3.897)   | 0.272           | 1.599 (0.769–3.326)   | 0.209           |
| Lymph node invasion     | 1.689 (0.530–5.387)   | 0.376           | 1.493 (0.675–3.306)   | 0.322           |
| Grading 3–4             | 1.463 (0.602–3.555)   | 0.401           | 1.930 (1.014–3.671)   | 0.045           |
| UICC stage III/IV       | 1.225 (0.388–3.873)   | 0.730           | 2.062 (0.921–4.615)   | 0.078           |
| Tumor number            | 1.298 (0.510–3.306)   | 0.584           | 1.159 (0.561–2.393)   | 0.690           |
| CCI >40                 | 1.534 (0.667–3.527)   | 0.314           | 3.060 (1.589–5.893)   | 0.001           |
| Tumor recurrence        | n.a.                  | 1.522 (0.781–2.965) | 0.217                  |

Note: Due to multicollinearity, the following variables were not included in the multivariable analysis: adjuvant treatment (patient selection for therapy was associated with pathological risk factors [nodal status, R status] in the pre-BILCAP era), T category (collinearity with UICC staging), ICU and hospital stay (collinearity with transfusions and CCI), tumor size (collinearity with UICC staging). Abbreviations: BILCAP, Capecitabine Compared With Observation in Resected Biliary Tract Cancer; CCA, cholangiocarcinoma; CCI, comprehensive complication index; CI, confidence interval; FFP, fresh-frozen plasma; iCCA, intrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; UICC, Union Internationale Contre le Cancer.

<sup>a</sup>p < 0.5 is significant.

<sup>b</sup>Not significant in univariable analysis (log-rank test).
REFERENCES

1. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.
2. Rizvi S, Khan SA, Hallemeyer CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111.
3. Li J, Moustafa M, Linecker M, Lurje G, Capobianco I, Baumgart J, et al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery Lead to the oncological benefit? An international multi-center study. Ann Surg Oncol. 2020;27:1372–84.
4. Cements O, Eliahou J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95–103.
5. Hunter LA, Soares HP. Quality of life and symptom management in advanced biliary tract cancers. Cancer. 2021;13(20):5074.
6. Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597–605.
7. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.
8. European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93.
9. Uluk D, Pratschke J, Lurje G. Influence of skeletal muscle mass on graft regeneration after living-donor liver transplantation. Hepatobiliary Surg Nutr. 2021;10(4):564–6.
10. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
11. Engelmann C, Schwandt C, Rentrop S, Moers U, Uhl F, Loffler L, et al. Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Aliment Pharmacol Ther. 2018;48(11–12):1271–81.
12. Czizgany Z, Krapf W, Bednarsch J, van der Krol G, Boecker J, Strnad P, et al. Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation. Am J Transplant. 2020;20(2):493–503.
13. Czizgany Z, Krapf W, Lurje I, Miller H, Bednarsch J, Lang SA, et al. The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. J Cachexia Sarcopenia Muscle. 2021;12(2):358–67.
14. Bednarsch J, Czizgany Z, Lurje I, Amygdalos I, Strnad P, Halm P, et al. Insufficient future liver remnant and preoperative cholangitis predict perioperative outcome in perihilar cholangiocarcinoma. HPB (Oxford). 2021;23(1):99–108.
15. Bednarsch J, Czizgany Z, Lurje I, Tacke F, Strnad P, Ulmer TF, et al. Left- versus right-sided hepatectomy with hilar en bloc resection in perihilar cholangiocarcinoma. HPB (Oxford). 2020;22(3):437–44.
16. Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schliwer W, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012;19(5):1602–8.
17. Lurje G, Bednarsch J, Czizgany Z, Lurje I, Schlebusch IK, Boecker J, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2019;45(8):1468–78.
18. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15(22):6973–9.
19. Clavien PA, Barkun J, de Oliveira ML, Vauthen JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
20. Slankamenak C, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):7–17.
21. Rahbari NN, Garden CJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the international study Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713–24.
22. Merath K, Chen Q, Bagante F, Beal E, Akgul O, Dillhoff M, et al. Textbook outcomes among Medicare patients undergoing hepatopancreatic surgery. Ann Surg. 2020;271(6):1116–23.
23. Hyder O, Marques H, Pulliano C, Marsh JW, Alexandrescu S, Bauer TW, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149(5):432–8.
24. Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011;53(4):1363–71.
25. Bednarsch J, Czizgany Z, Lurje I, Strnad P, Bruners P, Ulmer TF, et al. The role of ALPPS in intrahepatic cholangiocarcinoma. Langenbecks Arch Surg. 2019;404(7):885–94.
26. Lurje I, Czizgany Z, Bednarsch J, Gaisa NT, Dahl E, Knüchel R, et al. Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma. Liver Cancer. 2022;11:162–73.
27. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.
28. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187–96.
29. Schlesinger S, Siegert S, Koch M, Walter J, Heits N, Hinz S, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014;25(10):1407–18.
30. Chen HN, Chen XZ, Zhang WH, Yang K, Chen XL, Zhang B, et al. The impact of body mass index on the surgical outcomes of patients with gastric cancer: a 10-year, single-institution cohort study. Medicine (Baltimore). 2015;94(42):e1769.
31. Caan BJ, Cespedes Feliciano EM, Kroenke CH. The importance of body composition in explaining the overweight paradox in cancer-counterpoint. Cancer Res. 2018;78(8):1906–12.
32. Arglés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–6.
33. Wiedmer P, Jung T, Castro JP, Pomatto LCD, Sun PY, Davies KJA, et al. Sarcopenia—molecular mechanisms and open questions. Ageing Res Rev. 2021;65:101200.
34. Schrager MA, Metter EJ, Simonick E, Ble A, Bandinelli S, Lauretani F, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol (1985). 2007;102(3):919–25.
35. Ruffolo LI, Ullman N, Melucci A, Qin S, Juvilier P, Kaur R, et al. Sarcopenia, cachexia and cholangiocarcinoma: implications on prognosis and immunomodulation. HPB. 2020;22(Suppl 1):S53–4.
36. Tamura S, Ashida R, Sugita T, Okamura Y, Ito T, Yamamoto Y, et al. The prognostic impact of skeletal muscle status and bone mineral density for resected distal cholangiocarcinoma. Clin Nutr. 2021;40(5):3552–8.
37. Chakedis J, Spolverato G, Beal E, Akgul O, Dillhoff M, et al. Pre-operative sarcopenia identifies patients at risk for poor survival after resection of biliary tract cancers. J Gastrointest Surg. 2018;22(10):1697–708.
38. Jördens MS, Wittig L, Heinrichs L, Keitel V, Schulze-Hagen M, Antoch G, et al. Sarcopenia and myosteatosis as prognostic markers in patients with advanced cholangiocarcinoma undergoing palliative treatment. J Clin Med. 2021;10(19):4340.
39. Jördens MS, Heinrichs L, Loosen SH, Wittig L, Keitel V, Schöler D, et al. Sarcopenia predicts cancer mortality in male but not in female patients undergoing surgery for cholangiocellular carcinoma. Cancer (Basel). 2021;13(21):5359.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.